I
159.79
7.54 (4.95%)
| 前收盘价格 | 152.25 |
| 收盘价格 | 157.69 |
| 成交量 | 1,523,750 |
| 平均成交量 (3个月) | 1,485,811 |
| 市值 | 11,067,801,600 |
| 市盈率 (P/E TTM) | 37.33 |
| 预期市盈率 (P/E Forward) | 24.75 |
| 价格/销量 (P/S) | 3.76 |
| 股市价格/股市净资产 (P/B) | 8.18 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2026 |
| 营业毛利率 | 18.29% |
| 营业利益率 (TTM) | 15.61% |
| 稀释每股收益 (EPS TTM) | 5.54 |
| 季度收入增长率 (YOY) | 28.80% |
| 季度盈利增长率 (YOY) | -31.30% |
| 总债务/股东权益 (D/E MRQ) | 131.40% |
| 流动比率 (MRQ) | 4.47 |
| 营业现金流 (OCF TTM) | 406.50 M |
| 杠杆自由现金流 (LFCF TTM) | 84.25 M |
| 资产报酬率 (ROA TTM) | 6.94% |
| 股东权益报酬率 (ROE TTM) | 37.92% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 看跌 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Insulet Corporation | 混合的 | 看跌 |
AIStockmoo 评分
0.1
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.13 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Mid Growth |
| 内部持股比例 | 0.29% |
| 机构持股比例 | 102.56% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合